23 September 2010
Eurovestech plc
(the "Company")
Charitable Donations
The Company announces that it has issued 400,000 new ordinary shares in the
issued share capital of Eurovestech (the "Charity Shares") as follows;
Number of Ordinary Shares
Evening Standard Distressed Fund 200,000
Imperial College Healthcare 100,000
Yorkshire Cancer Research 100,000
Richard Bernstein, Chief Executive of the Company, has paid the £4,000 to
facilitate their issue, representing the nominal value of these shares of 1
pence per share. Application has been made for the Charity Shares to be
admitted to AIM and it is expected that dealings will commence on 30 September
2010. Following admission, the Company will have 330,650,000 ordinary shares in
issue.
ENQUIRIES:
Eurovestech plc
Richard Bernstein Tel: 020 7491 0770
Merchant Securities Limited (NOMAD)
David Worlidge/Simon Clements Tel: 020 7628 2200
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.